Journal of Substance Abuse Treatment 23 (2002) 447 – 448
Keyword index Volume 23, 2002 Abstinence, 209, 247 Addiction, 55, 319 Addictions treatment, 41 Adolescents, 21, 123, 231 AIDS, 437 Alcohol, 399 Alcohol consumption, 247 Alcohol dependence, 419 Alcohol screening, 419 Alcohol treatment, 247 Alcohol use disorders, 247 Alcoholism, 9, 361 Ambulatory care, 239 Attrition, 431 Behavior therapy, 351, 335 Behavioral therapies, 73 Brief interventions, 1 Buprenorphine, 87, 93, 163, 415 Case management, 387 Clinical Trials Network, 55 Club drugs, 151 Cocaine, 33 Cocaine abuse, 191 Cognitive behavioral, 343 Cognitive behavioral therapy, 191 Cognitive therapy, 335 Collaboration, 157 Compliance, 81 Contingency management, 81 Continuing care, 21 Controlled, 9 Controlled drinking, 361 Coping, 343 Counselor characteristics, 327 Crime, 261 Delinquency, 231 Dental care, 239 Detoxification, 163, 183, 253, 399 Disparities in access, 199 Diversion programs, 217 Dose response, 191
Dosing, 409 Drop-out, 431 Drug abuse, 107, 151, 171, 239, 253, 343 Drug courts, 217 Drug dependence, 183 Drug discrimination, 409 Drug-drug interactions, 93 Drug offenders, 217 Drugs, 399 Drug treatment outcome, 327 Dual diagnosis, 115 Dually diagnosed, 297 Ecstasy, 151 Employment, 261 Engagement, 375 Ethics, 55 Experiment, 21 Family members, 171 Family therapy, 123 Follow-up, 361 FTND, 367 Gender, 285, 399 Gender-specific treatment, 41 GHB, 151 Hallucinogens, 273 Heroin, 231, 351 Heroin addiction, 93, 273 Heroin dependence, 163 HIV, 319 HIV/AIDS, 49 HIV infection, 93, 239 Human subjects protection, 55 Identification, 209, 375 Illicit drug use, 335 Incentives, 81 Initiation, 375 Injection drug use, 225 Iran, 415 Ketamine, 151, 273
0740-5472/02/$ – see front matter D 2002 Elsevier Science Inc. All rights reserved. PII: S 0 7 4 0 - 5 4 7 2 ( 0 2 ) 0 0 3 4 1 - 0
448
Keyword index / Journal of Substance Abuse Treatment 23 (2002) 447–448
LAAM (levomethadyl acetate), 93 Length of stay, 261 Linking research and practice, 157 Manual driven psychotherapy, 191 Manuals, 107 MDMA, 151 Measurement, 375 Medications, 145 Mental health services, 239 Methadone, 231, 319 Methadone maintenance, 409, 425 Methadone maintenance treatment, 93 Methamphetamine, 145, 151 Minimal treatment, 9 Motivational intervention, 183 Motivational interviewing, 49, 73, 297 Naltrexone, 351, 361 Narcotics Anonymous, 61 Needs assessment, 199 Neuropsychological screening, 133 Nursing home, 437 Office-based pharmacotherapy, 93 Opiate dependence, 87, 335 Opiates, 319, 409 Opium dependence, 415 Outcome, 33, 361 Outpatient, 9, 107 Oxford House, 209 Partnership Research-practice gap, 157 Performance, 375 Pharmacotherapy, 87 Policy, 87 Practice, 87 Predictors, 425 Preliminary outcomes, 21 Problem drinking, 1 Program evaluation, 217 Prostitution, 49 Psychedelics, 273 Psychiatric comorbidity, 163 Psychiatric hospitalization, 163 Psychological assessment, 133 Psychopathology, 431 Psychosocial issues, 41 Psychotherapy, 273, 309 Psychotic disorder, 297 Randomized clinical trials, 73 Rehabilitation, 253 Relapse, 399 Relapse prevention, 343 Research, 87, 145
Research-practice, 123 Retention, 387, 431 Retention in treatment, 415 Risk reduction, 225 SASSI-3, 419 Selection bias, 387 Self-efficacy, 209 Self-esteem, 437 Self-help, 61 Serotonin, 33 Service coordination, 115 Service delivery model, 115 Sex differences, 335 Small areas, 199 Smoking cessation, 367 Social adjustment, 171 Social functioning, 171 Social network, 225 Social support, 61, 209 Spirituality, 319 Staff beliefs, 55 Stimulants, 107, 145 Substance abuse, 123, 157, 253, 285, 261, 297, 309, 387, 437 Substance abuse indicators, 199 Substance abuse treatment, 61, 73, 81, 217, 133 Substance use disorders, 21, 49 Technology transfer, 309 Therapeutic community, 437 Tobacco cessation, 425 Tobacco dependence, 367 Training, 309 Treatment, 33, 107, 145, 273, 351 Treatment approaches, 115 Treatment completion, 261, 285 Treatment effectiveness, 387 Treatment engagement, 297 Treatment entry, 183 Treatment initiation, 285 Treatment matching, 367 Treatment outcome, 9 Treatment retention, 285 Treatment service gaps, 199 Treatment system, 183 Treatment-resistant, 335 Trends, 253 Untreated controls, 247 Urine drug screen, 33 Veterans, 41 Vouchers, 81 Withdrawal, 409 Women, 1, 41, 49, 133, 171, 431